In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy
暂无分享,去创建一个
Marc Dhenain | Thierry Delzescaux | Thomas Debeir | Thomas Rooney | Michel E. Vandenberghe | Anne-Sophie Herard | M. Dhenain | T. Delzescaux | L. Pradier | A. Hérard | T. Rooney | M. Santin | Laurent Pradier | T. Debeir | Mathieu D. Santin | Caroline Cohen | Caroline Cohen
[1] Thomas Wisniewski,et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.
[2] Thomas Wisniewski,et al. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice , 2008, Neurobiology of Aging.
[3] Marc Dhenain,et al. Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood–brain barrier opening , 2013, NeuroImage.
[4] T. Golde. Alzheimer disease therapy: can the amyloid cascade be halted? , 2003, The Journal of clinical investigation.
[5] D. Galimberti,et al. Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment , 2014, Neuroimmunomodulation.
[6] Lawrence M. Wein,et al. A mathematical model of the impact of novel treatments on the Aβ burden in the Alzheimer’s brain, CSF and plasma , 2015, Bulletin of mathematical biology.
[7] C. Islak,et al. Intrathecal Gadolinium-Enhanced MR Cisternography in the Evaluation of CSF Leakage , 2010, American Journal of Neuroradiology.
[8] L. Lue,et al. Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibody‐opsonized amyloid beta peptide , 2002, Journal of neuroscience research.
[9] A. Mironov,et al. Intrathecal Gadolinium (Gadopentetate Dimeglumine) Enhanced Magnetic Resonance Myelography and Cisternography: Results of a Multicenter Study , 2002, Investigative radiology.
[10] T. Bayer,et al. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice , 2003, Experimental Neurology.
[11] Gheorghe Iordanescu,et al. Automatic segmentation of amyloid plaques in MR images using unsupervised support vector machines , 2012, Magnetic resonance in medicine.
[12] Kullervo Hynynen,et al. Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound , 2013, Experimental Neurology.
[13] S. Lehéricy,et al. Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats , 2016, Investigative radiology.
[14] Thomas Wisniewski,et al. Immunotherapeutic Approaches for Alzheimer’s Disease , 2015, Neuron.
[15] Whole Grain Label Statements. Guidance for Industry and FDA Staff , 2006 .
[16] Yvonne S. Eisele,et al. From Soluble Aβ to Progressive Aβ Aggregation: Could Prion‐Like Templated Misfolding Play a Role? , 2013, Brain pathology.
[17] Donald W. Miller,et al. Rapid and Reversible Enhancement of Blood–Brain Barrier Permeability Using Lysophosphatidic Acid , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] G. Dai,et al. Coenzyme Q10 Reduces β-Amyloid Plaque in an APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease , 2010, Journal of Molecular Neuroscience.
[19] N. Dubin. Mathematical Model , 2022 .
[20] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[21] Tom Misteli,et al. In vivo imaging. , 2003, Methods.
[22] C. Finch,et al. Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.
[23] Florence Pasquier,et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? , 2002, Experimental Gerontology.
[24] W. H. Jordan,et al. A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice , 2012, Neuron.
[25] Marc Dhenain,et al. Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice , 2012, Neurobiology of Aging.
[26] Pascal J. Kieslich,et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.
[27] Nobuhisa Iwata,et al. 19F and 1H MRI detection of amyloid β plaques in vivo , 2005, Nature Neuroscience.
[28] J. Herms,et al. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer’s disease mouse model , 2014, Brain : a journal of neurology.
[29] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[30] B. Liu,et al. Amyloid-β Immunotherapy for Alzheimers Disease , 2010 .
[31] Tetsuya Suhara,et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.
[32] Marc Dhenain,et al. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice , 2009, Neurobiology of Aging.
[33] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] Roy Jefferis,et al. Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.
[35] M. Dhenain,et al. Passive staining: A novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease , 2006, Magnetic resonance in medicine.
[36] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[37] Markus Rudin,et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe , 2005, Nature Biotechnology.
[38] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[39] A. Doerfler,et al. MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T , 2016, European Radiology.
[40] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[41] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[42] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[43] A. Volk,et al. Morphological and carbogen‐based functional MRI of a chemically induced liver tumor model in mice , 2003, Magnetic resonance in medicine.
[44] Thomas Wisniewski,et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging , 2008, Journal of Neuroscience Research.
[45] B. Rutt,et al. Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease , 2015, Neurobiology of Aging.
[46] Marc Dhenain,et al. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease , 2010, NeuroImage.
[47] Clifford R Jack,et al. In Vivo Magnetic Resonance Microimaging of Individual Amyloid Plaques in Alzheimer's Transgenic Mice , 2005, The Journal of Neuroscience.
[48] Qing X Yang,et al. MRI and histological analysis of beta‐amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice , 2009, Journal of magnetic resonance imaging : JMRI.
[49] In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques , 2014, Acta neuropathologica communications.
[50] Ryan Chamberlain,et al. Comparison of amyloid plaque contrast generated by T2‐weighted, T 2* ‐weighted, and susceptibility‐weighted imaging methods in transgenic mouse models of Alzheimer's disease , 2009, Magnetic resonance in medicine.
[51] D. Selkoe,et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.
[52] R. Floris,et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. , 2013, European journal of radiology.
[53] S. DeKosky,et al. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.
[54] Thomas Wisniewski,et al. Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging , 2002, Neurobiology of Disease.
[55] H. Braak,et al. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. , 2015, Brain : a journal of neurology.
[56] H. Fukuyama,et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.
[57] Marc Dhenain,et al. Senile plaques do not induce susceptibility effects in T 2*‐weighted MR microscopic images , 2002, NMR in biomedicine.
[58] Nobuhisa Iwata,et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. , 2005, Nature neuroscience.
[59] A. Petiet,et al. In Vivo Imaging Biomarkers in Mouse Models of Alzheimer's Disease: Are We Lost in Translation or Breaking Through? , 2010, International journal of Alzheimer's disease.
[60] Agneta Nordberg,et al. Amyloid imaging in Alzheimer's disease , 2007, Neuropsychologia.
[61] J. Ravetch,et al. SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA) , 2013, Alzheimer's & Dementia.
[62] C. Finch,et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[63] C. Lemere,et al. Amyloid-beta immunotherapy for Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.
[64] Marc Dhenain,et al. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice , 2006, Neurobiology of Aging.
[65] T. Wisniewski. Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced MR Imaging , 2002 .